Literature DB >> 19459072

Incidence of microsporidia in cancer patients.

Angela R Lono1, Suresh Kumar, Tan T Chye.   

Abstract

INTRODUCTION: Microsporidia are considered opportunistic pathogens as evidenced by the significant detection in immunocompromised HIV/AIDS population. Cancer patients receiving chemotherapy are considered to be immunosuppressed.
MATERIALS AND METHODS: Stool samples were collected from 311 cancer patients in the Klang Valley. Each sample underwent water-ether concentration and staining with modified trichrome stain. RESULTS AND DISCUSSION: Sixty-eight samples were positive by oil immersion examination. Polymerase chain reaction amplification with specific primers on those samples amplified Encephalitozoon intestinalis from two of the samples and Encephalitozoon hellem from one sample.

Entities:  

Mesh:

Year:  2009        PMID: 19459072     DOI: 10.1007/s12029-009-9065-z

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  25 in total

1.  Intestinal parasites in Malaysian children with cancer.

Authors:  B S Menon; M S Abdullah; F Mahamud; B Singh
Journal:  J Trop Pediatr       Date:  1999-08       Impact factor: 1.165

2.  In vitro culture, ultrastructure, antigenic, and molecular characterization of Encephalitozoon cuniculi isolated from urine and sputum samples from a Spanish patient with AIDS.

Authors:  C del Aguila; H Moura; S Fenoy; R Navajas; R Lopez-Velez; L Li; L Xiao; G J Leitch; A da Silva; N J Pieniazek; A A Lal; G S Visvesvara
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

3.  Intestinal infections in patients with the acquired immunodeficiency syndrome (AIDS). Etiology and response to therapy.

Authors:  P D Smith; H C Lane; V J Gill; J F Manischewitz; G V Quinnan; A S Fauci; H Masur
Journal:  Ann Intern Med       Date:  1988-03       Impact factor: 25.391

4.  Detection of Enterocytozoon bieneusi (Microsporidia) by polymerase chain reaction (PCR) using species-specific primer in stool samples of HIV patients.

Authors:  S Satheesh Kumar; S Ananthan; A G Joyee
Journal:  Indian J Med Res       Date:  2005-04       Impact factor: 2.375

5.  Sensitive PCR diagnosis of Infections by Enterocytozoon bieneusi (microsporidia) using primers based on the region coding for small-subunit rRNA.

Authors:  A J da Silva; D A Schwartz; G S Visvesvara; H de Moura; S B Slemenda; N J Pieniazek
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

6.  Detection of the microsporidian parasite Enterocytozoon bieneusi in specimens from patients with AIDS by PCR.

Authors:  J N Velásquez; S Carnevale; E A Guarnera; J H Labbé; A Chertcoff; M G Cabrera; M I Rodríguez
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

7.  A case of pulmonary Microsporidiasis in an acute myeloblastic leukemia (AML) - M3 patient.

Authors:  Süleyman Yazar; Bülent Eser; Saban Yalçin; Izzet Sahin; A Nedret Koç
Journal:  Yonsei Med J       Date:  2003-02       Impact factor: 2.759

8.  A preliminary study of the prevalence of intestinal parasites in immunocompromised patients with and without gastrointestinal manifestations.

Authors:  Jorge Humberto Botero; Amanda Castaño; Marta Nelly Montoya; Norma Elena Ocampo; Marta Inés Hurtado; Mónica María Lopera
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2003-09-17       Impact factor: 1.846

Review 9.  Utility of microsporidian rRNA in diagnosis and phylogeny: a review.

Authors:  L M Weiss; X Zhu; A Cali; H B Tanowitz; M Wittner
Journal:  Folia Parasitol (Praha)       Date:  1994       Impact factor: 2.122

Review 10.  Gastrointestinal disease in the immunocompromised patient.

Authors:  H Rotterdam; P Tsang
Journal:  Hum Pathol       Date:  1994-11       Impact factor: 3.466

View more
  9 in total

Review 1.  Effector CD8 T cell immunity in microsporidial infection: a lone defense mechanism.

Authors:  Magali M Moretto; Danielle I Harrow; Imtiaz A Khan
Journal:  Semin Immunopathol       Date:  2015-04-10       Impact factor: 9.623

Review 2.  Microsporidiosis: not just in AIDS patients.

Authors:  Elizabeth S Didier; Louis M Weiss
Journal:  Curr Opin Infect Dis       Date:  2011-10       Impact factor: 4.915

3.  Immune Response to Microsporidia.

Authors:  Magali M Moretto; Imtiaz A Khan
Journal:  Exp Suppl       Date:  2022

4.  The first study on opportunistic intestinal microsporidiosis in IBD patients receiving immunosuppressive medications in Iran.

Authors:  Z Hasani; H Asadzadeh Aghdaei; H Balaii; M Azimirad; E S Mirsamadi; H Mirjalali; M R Zali
Journal:  Epidemiol Infect       Date:  2017-05-15       Impact factor: 4.434

5.  Intestinal microsporidiosis in Iran: infection in immune-compromised and immunocompetent patients.

Authors:  M Nooshadokht; I Sharifi; M A Mohammadi; M Pirestani; A Afgar; A Mahootchi; S Salari
Journal:  Curr Med Mycol       Date:  2017-03

6.  Microbial Signatures Associated with Oropharyngeal and Oral Squamous Cell Carcinomas.

Authors:  Sagarika Banerjee; Tian Tian; Zhi Wei; Kristen N Peck; Natalie Shih; Ara A Chalian; Bert W O'Malley; Gregory S Weinstein; Michael D Feldman; James Alwine; Erle S Robertson
Journal:  Sci Rep       Date:  2017-06-22       Impact factor: 4.379

7.  Enteric Opportunistic Infection and the Impact of Antiretroviral Therapy among HIV/AIDS Patients from Tehran, Iran.

Authors:  Hossein Masoumi-Asl; Khadijeh Khanaliha; Farah Bokharaei-Salim; Abdoulreza Esteghamati; Saeed Kalantari; Maryam Hosseinyrad
Journal:  Iran J Public Health       Date:  2019-04       Impact factor: 1.429

8.  Encephalitozoon intestinalis infection increases host cell mutation frequency.

Authors:  Cory Ann Leonard; Maria Schell; Robert Vincent Schoborg; James Russell Hayman
Journal:  Infect Agent Cancer       Date:  2013-11-04       Impact factor: 2.965

9.  Genotyping of Enterocytozoon bieneusi and Subtyping of Blastocystis in Cancer Patients: Relationship to Diarrhea and Assessment of Zoonotic Transmission.

Authors:  Weizhe Zhang; Guangxu Ren; Wei Zhao; Ziyin Yang; Yujuan Shen; Yihua Sun; Aiqin Liu; Jianping Cao
Journal:  Front Microbiol       Date:  2017-09-21       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.